Novel oral anticoagulants in Non-Valvular atrial fibrillation

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2014, Pages 3-8

  da Silva, Rose M F L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anticoagulants agents; Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Systemic embolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANEMIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISEASE ASSOCIATION; DYSPEPSIA; EPISTAXIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TANDEM MASS SPECTROMETRY; THROMBIN TIME; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; ECONOMICS; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; STANDARDS; TRENDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CHEMISTRY, PHARMACEUTICAL; DABIGATRAN; HUMANS; MORPHOLINES; RIVAROXABAN; THIOPHENES;

EID: 84925448246     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152571201141201091848     Document Type: Article

References (42)

1. Camm, A.J.; Lip, G.Y.; de Caterina, R.; Savelieva, I.; Atar, D.; Hohnloser, S.H.; Hindricks, G.; Kirchhof, P.; Bax, J.J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Popescu, B.A.; Reiner, Z.; Sechtem, U.; Sirnes, P.A.; Tendera, M.; Torbicki, A.; Vahanian, A.; Windecker, S.; Vardas, P.; Al-Attar, N.; Alfieri, O.; Angelini, A.; Blomstrom-Lundqvist, C.; Colonna, P.; De Sutter, J.; Ernst, S.; Goette, A.; Gorenek, B.; Hatala, R.; Heidbuchel, H.; Heldal, M.; Kristensen, S.D.; Le Heuzey, J.Y.; Mavrakis, H.; Mont, L.; Filardi, P.P.; Ponikowski, P.; Prendergast, B.; Rutten, F.H.; Schotten, U.; van Gelder, I.C.; Verheugt, F.W. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart. J., 2012, 33 (21), 2719-2747.
2. January, C.T.; Wann, L.S.; Alpert, J.S.; Calkins, H.; Cleveland, J.C.Jr.; Cigarroa, J.E.; Conti, J.B.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Murray, K.T.; Sacco, R.L.; Stevenson, W.G.; Tchou, P.J.; Tracy, C.M.; Yancy, C.W. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 2014 Mar 28. [Epub ahead of print].
3. Davis, R.C.; Hobbs, F.D.; Kenkre, J.E.; Roalfe, A.K.; Iles, R.; Lip, G.Y.; Davies M.K. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace., 2012, 14(11), 1553-1559.
4. Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke., 1991, 22(8), 983-988.
5. Kirchhof, P.; Ammentorp, B.; Darius, H.; De Caterina, R.; Le Heuzey, J.Y.; Schilling, R.J.; Schmitt, J.; Zamorano, J.L. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines onatrial fibrillation: primary results of the PREvention oF thromboemolic events-- European Registry in Atrial Fibrillation (PREFER in AF). Europace., 2014, 16 (1), 6-14.
6. Ogilvie, I.M.; Newton, N.; Welner, S.A.; Cowell, W.; Lip, G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med., 2010, 123 (7), 638-645.
7. Connolly, S.J.; Pogue, J.; Eikelboom, J.; Flaker, G.; Commerford, P.; Franzosi, M.G.; Healey, J.S.; Yusuf, S.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation., 2008, 118 (20), 2029-2037.
8. Harburger, J.M.; Aronow, W.S. Newer anticoagulants for nonvalvular atrial fibrillation. Pharmaceuticals (Basel)., 2012, 5 (5), 469-480.
9. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A; Themeles, E.; Varrone, J.; Wang, S.; Alings, M.; Xavier, D.; Zhu, J.; Diaz, R.; Lewis, B.S.; Darius, H.; Diener, H.C.; Joyner, C.D.; Wallentin, L.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361 (12), 1139-1151.
10. Beasley, B.N.; Unger, E.F.; Temple, R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med., 2011, 364 (19), 1788-1790.
11. Katsnelson, M.; Sacco, R.L.; Moscucci, M. Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. Circulation., 2012, 125 (12), 1577-1583.
12. Gallego, P.; Roldán, V.; Lip, G.Y. Novel oral anticoagulants in cardiovascular disease. J. Cardiovasc. Pharmacol. Ther., 2014, 19 (1), 34-44.
13. Harder, S.; Graff, J. Novel oral anticoagulants: Clinical pharmacology, indications and practical considerations. Eur. J. Clin. Pharmacol., 2013, 69 (9),1617-1633.
14. Potpara, T.S.; Lip, G.Y. Novel oral anticoagulants in non-valvular atrial fibrillation. Best. Pract. Res. Clin. Haematol., 2013, 26 (2), 115-129.
15. Boos, C.J.; Nam, M.; Camm, A.J. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart. Fail. Rev., 2014, 19 (3), 391-401.
16. Southworth, M.R.; Reichman, M.E.; Unger, E.F. Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med., 2013, 368 (14), 1272-1274.
17. Larsen, T.B.; Rasmussen, L.H.; Gorst-Rasmussen, A.; Skjøth, F.; Rosenzweig, M.; Lane, D.A.; Lip, G.Y. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am. J. Med., 2014, 127 (4), 329-336.
18. European Medicines Agency. (www.ema.europa.eu/Find medicine/ Human medicines/European Public Assessment Reports). Accessed May 28, 2014.
19. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; Becker, R.C.; Nessel, C.C.; Paolini, J.F.; Berkowitz, S.D.; Fox, K.A.; Califf, R.M.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 2011, 365 (10), 883-891.
20. Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M.C.; Diaz, R.; Easton, J.D.; Ezekowitz, J.A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B.J.; Golitsyn, S.; Goto, S.; Hermosillo, A.G.; Hohnloser, S.H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B.S.; Lopez-Sendon, J.L.; Pais, P.; Parkhomenko, A.; Verheugt, F.W.; Zhu, J.; Wallentin, L.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2011, 365 (11), 981-992.
21. deWald, T.A.; Becker, R.C. The pharmacology of novel oral anticoagulants. J. Thromb. Thrombolysis, 2014, 37 (2), 217-233.
22. Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Špinar, J.; Ruzyllo, W.; Ruda, M.; Koretsune, Y.; Betcher, J.; Shi, M.; Grip, L.T.; Patel, S.P.; Patel, I.; Hanyok, J.J.; Mercuri, M.; Antman, E.M.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2013, 369 (22), 2093-2104.
23. Chan, N.C.; Hirsh, J.; Ginsberg, J.S.; Eikelboom, J.W. Betrixaban (PRT054021): Pharmacology, dose selection and clinical studies. Future. Cardiol., 2014, 10 (1), 43-52.
24. Dentali, F.; Riva, N.; Crowther, M.; Turpie, A.G.; Lip, G.Y.; Ageno, W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation, 2012, 126 (20), 2381-2391.
25. Miller, C.S.; Grandi, S.M.; Shimony, A.; Filion, K.B.; Eisenberg, M.J. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol., 2012, 110 (3), 453-460.
26. Mitchell, S.A.; Simon, T.A.; Raza, S.; Jakouloff, D.; Orme, M.E.; Lockhart, I.; Drost, P. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. Clin. Appl. Thromb. Hemost., 2013, 19 (6), 619-631.
27. Ruff, C.T.; Giugliano, R.P.; Braunwald, E.; Hoffman, E.B.; Deenadayalu, N.; Ezekowitz, M.D.; Camm, A.J.; Weitz, J.I.; Lewis, B.S.; Parkhomenko, A.; Yamashita, T.; Antman, E.M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014, 383 (9921), 955-962.
28. Pancholy, S.B.; Sharma, P.S.; Pancholy, D.S.; Patel, T.M.; Callans, D.J.; Marchlinski, F.E. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am. J. Cardiol., 2014, 113 (3), 485-490.
29. Harrington, A.R.; Armstrong, E.P.; Nolan, P.E.Jr.; Malone, D.C. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke., 2013, 44 (6), 1676-1681.
30. Pink, J.; Pirmohamed, M.; Hughes, D.A. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin. Pharmacol. Ther., 2013, 94 (2), 269-276.
31. Rognoni, C.; Marchetti, M.; Quaglini, S.; Liberato, N.L. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: acost-effectiveness analysis. Clin. Drug. Investig., 2014, 34 (1), 9-17.
32. Desai, N.R.; Krumme, A.A.; Schneeweiss, S.; Shrank, W.H.; Brill, G.; Pezalla, E.J.; Spettell, C.M.; Brennan, T.A.; Matlin, O.S.; Avorn, J.; Choudhry, N.K. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation - Quality and Cost Implications. Am. J. Med., 2014 May 20. [Epub ahead of print].
33. Lip, G.Y.H.; Kongnakorn, T.; Phatak, H.; Kuznik, A.; Lanitis, T.; Liu, L.Z.; Iloeje, U.; Hernandez, L.; Dorian, P. Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clin. Therap., 2014, 36 (2), 192- 210.
34. Heidbuchel, H.; Verhamme, P.; Alings, M.; Antz, M.; Hacke, W.; Oldgren, J.; Sinnaeve, P.; Camm, A.J.; Kirchhof, P.; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace., 2013, 15 (5), 625- 651.
35. Deitelzweig, S. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation. Cardiovasc. Ther., 2014, 32 (2), 74-81.
36. Haas, S.; Bode, C.; Norrving, B.; Turpie, A.G. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc. Health. Risk. Manag., 2014, 10, 101-114.
37. Flaker, G.; Lopes, R.D.; Al-Khatib, S.M.; Hermosillo, A.G.; Hohnloser, S.H.; Tinga, B.; Zhu, J.; Mohan, P.; Garcia, D.; Bartunek, J.; Vinereanu, D.; Husted, S.; Harjola, V.P.; Rosenqvist, M.; Alexander, J.H.; Granger, C.B.; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLETrial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J. Am. Coll. Cardiol., 2014, 63 (11), 1082-1087.
38. Reynolds, M.R. Cardioversion With Novel Oral Anticoagulants. Reconfirming a 50-Year-Old Standard*. J. Am. Coll. Cardiol., 2014, 63 (11), 1088-1089.
39. Weitz, J.I.; Healey, J.S.; Skanes, A.C.; Verma, A. Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation, 2014, 129 (16), 1688-1694.
40. Birnie, D.H.; Healey, J.S.; Essebag, V. Management of anticoagulation around pacemaker and defibrillator surgery. Circulation, 2014, 129 (20), 2062-2065.
41. Siegal, D.M.; Crowther, M.A. Acute management of bleeding in patients on novel oral anticoagulants. Eur. Heart. J., 2013, 34 (7), 489-498b.
42. Hankey, G.J. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb. Haemost., 2014, 111 (5), 808-816.